

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/635,808
				Filing Date	August 5, 2003
				First Named Inventor	Rapin, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	NEURO 103

3354595\_1

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
MMCG	AA	5,212,158	A	VANDAI	05-18-1993	
	AB	5,973,111	A	BEMIS, et al.	10-26-1999	
	AC	6,156,572	A	BELLAMKONDA, et al.	12-05-2000	
MMCG	AD	6,235,929	B1	POWERS	05-22-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
MMCG	AE	EP	0,316,218	A1	INORGAN, S.A.	05-17-1989		
	AF	EP	1,018,341	A	CALPIS Co., Ltd.	07-12-2000		
	AG	EP	1,231,279	A1	CALPIS Co., Ltd.	08-14-2002		
	AH	EP	0,446,706	A2, A3	MERCK PATENT GESELLSCHAFT	09-18-1991		
	AI	JP	04-005240 w/ PAJ abstract	A	TAISHO PHARMACEUT. Co.;	01-09-1992		
	AJ	WO	88/09604	A2	MEDICIS Corp.	12-15-1988		
	AK	WO	92/11850	A2	CORTEX PHARMA; GA. TECH. RES. INST.	07-23-1992		
	AL	WO	96/41638	A1	SANOI WINTHROP	12-27-1996		
	AM	WO	98/14202	A1	AUCKLAND UNISERVICES, Ltd.	04-09-1998		
	AN	WO	01/28578	A2, A3	WRAIR	04-26-2001		
	AO	WO	01/34828	A1	CALPIS Co. Ltd.	05-17-2001		
	AP	WO	01/68114	A1	MONSANTO Co. (US)	09-20-2001		
	AQ	WO	02/062373	A2,A3	TELL PHARM. AG	08-15-2002		
MMCG	AR	WO	02/062828	A2,A3	TELL PHARM. AG	08-15-2002		

Examiner Signature	/Marcela M Cordero Garcia/	Date Considered	09/13/2006
-----------------------	----------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/635,808
				Filing Date	August 5, 2003
				First Named Inventor	Rapin, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	NEURO 103

3354595\_1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
MMCG	BA	BEYER, H., and WALTER, W., <i>Handbook of Organic Chemistry</i> , by S. Hirzel Verlag, Stuttgart (English translation of the 22 <sup>nd</sup> edition of <i>Lehrbuch der Organischen Chemie</i> ) (1996), pp. 827-838.	
	BB	BLUNDELL, T.L., et al., "Knowledge-based protein modelling and design", <i>Eur. J. Biochem.</i> , 172:513-520 (1988).	
	BC	CHESSEBEUF, M., et al., "Rat liver epithelial cell cultures in a serum-free medium: primary cultures and derived cell lines expressing differentiated functions", <i>In Vitro</i> , 20(10):780-795 (1984).	
	BD	CLARK, M.C., et al., "Validation of the general purpose Tripos 5.2 force field", <i>J. Comp. Chem.</i> , 10(8):982-1012 (1999).	
	BE	DE POOTER, H., et al., "N-acylamino acids and peptides IV the synthesis of N-cinnamyl-, N-p-coumaryl- and N-cafeyl-glycine and -glycyl-L-phenylalanine", <i>Bull. Soc. Chim. Belg.</i> , 85(9):647-656 (1976). XP008015013.	
	BF	FADEN, A.I., et al., "Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents", <i>Amer. J. Physiology</i> 277(4, pt. 2):R1196-R1204 (1999), <i>Chem. Abstr.</i> 132:31033 XP002207513, XP008014976.	
	BG	FADEN, A.I., et al., "Structure-activity relationships of TRH analogs in rat spinal cord injury", <i>Brain Research</i> , 448:287-293 (1988). XP008015202.	
	BH	GASTEIGER, J., et al., "Iterative partial equalization of orbital electronegativity -- a rapid access to atomic charges", <i>Tetrahedron</i> , 36:3219-3238 (1980).	
	BI	HAGG, T., et al., "Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage", <i>Exp. Neurol.</i> , 101:303-312 (1988).	
	BJ	JONES, D.T., et al., "A new approach to protein fold recognition", <i>Nature</i> , 358:86-89 (July 1992).	
	BK	JONES, D.T., "Protein secondary structure prediction based on position-specific scoring matrices", <i>J. Mol. Biol.</i> , 292(2):195-202 (1999).	
	BL	KANSY, M., et al. "Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes", <i>J. Med. Chem.</i> , 41(7):1007-1010 (March 26, 1998).	
MMCG	BM	KHUEBACHOVA, M., et al., "Mapping the C terminal epitope of the Alzheimer's disease specific antibody MN423", <i>J. Immunol. Methods (Elsevier Amsterdam, NL)</i> 262(1-2):205-215 (2002). XP004352190.	

Examiner Signature	/Marcela M Cordero Garcia/	Date Considered	09/13/2006
--------------------	----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/635,808
				Filing Date	August 5, 2003
				First Named Inventor	Rapin, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	NEURO 103

3354595\_1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
MMCG	CA	LASKOWSKI, R.A., et al., "PROCHECK: a program to check the stereochemical quality of protein structures", <i>J. Appl. Cryst.</i> , 26:283-291 (1993).			
	CB	LE PONCIN-LAFITTE, M., et al., "Sound-avoidance conditioning and a mathematical approach to the description of acquisition performance", <i>Math. Biosciences</i> , 59:249-268 (1982).			
	CC	LUCO, J.M., "Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling", <i>J. Chem. Inf. Comput. Sci.</i> , 39 (2):396-404 (1999)			
	CD	PARNETTI, L., et al., "Posatrelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid", <i>Acta Neurol. Scand.</i> 92:135-140 (1995).			
	CE	VARON, S., et al., "Nerve Growth Factor in CNS Repair", <i>J. Neurotrama</i> , 11(5) (1994)			
	CF	WANG, R., et al., "SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex", <i>J. Mol. Model.</i> , 4:379-394 (1998).			
	CG	WEINER, S.J., et al., "A new force field for molecular mechanical simulation of nucleic acids and proteins", <i>J. Am. Chem. Soc.</i> , 106:765-784 (1984)			
MMCG	CH	WIESMAN, C., et al., "Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor", <i>Nature</i> , 401:184 (September 9, 1999).			

3354595\_1

Examiner Signature	/Marcela M Cordero Garcia/	Date Considered	09/13/2006
--------------------	----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.